

- Nitiss JL. DNA topoisomerase II and its growing repertoire of biological functions. *Nat Rev Cancer* 2009;9(5):327–337.
- Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. *Nat Rev Cancer* 2009;9(5):338–350.
- Pommier Y, Leo E, Zhang H, et al. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. *Chem Biol* 2010;17(5):421–433.
- Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. *Prog Nucleic Acid Res Mol Biol* 2000;64:221–253.
- Wang JC. A journey in the world of DNA rings and beyond. *Annu Rev Biochem* 2009;78:31–54.
- Wang JC. Cellular roles of DNA topoisomerases: a molecular perspective. *Nat Rev Mol Cell Biol* 2002;3(6):430–440.
- Champoux JJ. DNA topoisomerases: structure, function, and mechanism. *Annu Rev Biochem* 2001;70:369–413.
- Wang JC. *Untangling the Double Helix: DNA Entanglements and the Action of DNA Topoisomerases*. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 2009.
- Pommier Y. DNA Topoisomerases and cancer. In: Teicher BA, ed. *Cancer Discovery and Development*. New York: Springer & Humana Press; 2012.
- Zhang H, Barceló JM, Lee B, et al. Human mitochondrial topoisomerase I. *Proc Natl Acad Sci U S A* 2001;98(10):10608–10613.
- Champoux JJ, Dulbecco R. An activity from mammalian cells that untwists superhelical DNA—a possible swivel for DNA replication (polyamethidium bromide-mouse-embryo cells-dye binding assay). *Proc Natl Acad Sci U S A* 1972;69(1):143–146.
- Chen SH, Wu CH, Plank JL, et al. Essential functions of C terminus of Drosophila Topoisomerase III α in double Holliday junction dissolution. *J Biol Chem* 2012;287(23):19346–19353.
- Xu D, Shen W, Guo R, et al. Top3 β is an RNA topoisomerase that works with fragile X syndrome protein to promote synapse formation. *Nat Neurosci* 2013;16(9):1238–1247.
- Seol Y, Gentry AC, Osheroff N, et al. Chiral discrimination and writhedependent relaxation mechanism of human topoisomerase II α . *J Biol Chem* 2013;288(19):13695–13703.
- Stoll G, Pietiläinen OP, Linder B, et al. Deletion of TOP3b, a component of FMRP-containing mRNPs, contributes to neurodevelopmental disorders. *Nat Neurosci* 2013;16(9):1228–1237.
- Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. *Nat Rev Drug Discov* 2011;11(1):25–36.
- Nitiss J, Wang JC. DNA topoisomerase-targeting antitumor drugs can be studied in yeast. *Proc Natl Acad Sci U S A* 1988;85(20):7501–7505.
- Bjornsti MA, Benedetti P, Vigilanti GA, et al. Expression of human DNA topoisomerase I in yeast cells lacking yeast DNA topoisomerase I: restoration of sensitivity of the cells to the antitumor drug camptothecin. *Cancer Res* 1989;49(22):6318–6323.
- Dressler LG, Berry DA, Broadwater G, et al. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. *J Clin Oncol* 2005;23(19):4287–4297.
- Holm C, Covey JM, Kerrigan D, et al. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and II inhibitors in Chinese hamster DC3F cell. *Cancer Res* 1989;49(22):6365–6368.
- Hsiang YH, Lihou MG, Liu LF. Arrest of DNA replication by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. *Cancer Res* 1989;49(18):5077–5082.
- Maeda Y, Shimizu H, Fukushima T, et al. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drug in a genetic DT40 repair screen panel. *Mol Cancer Ther* 2014;13(1):214–220.
- Huang SN, Pommier Y, Marchand C. Tyrosyl-DNA Phosphodiesterase 1(Tdp1) inhibitors. *Expert Opin Ther Pat* 2011;21(9):1285–1292.
- Zhang YW, Regairaz M, Seiler JA, et al. Poly(ADP-ribose) polymerase and XPF-ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells. *Nucleic Acids Res* 2011;39(9):3607–3620.
- Koster DA, Palle K, Bot ES, et al. Antitumor drugs impede DNA uncoiling by topoisomerase I. *Nature* 2007;448(7150):213–217.
- Sordet O, Redon CE, Guirouilh-Barbat J, et al. Ataxia telangiectasia mutated activation by transcription- and topoisomerase I-induced DNA double-strand breaks. *EMBO Rep* 2009;10(8):887–893.
- Pommier Y, Zwelling LA, Mattern MR, et al. Effects of dimethyl sulfoxide and thiourea upon intercalator-induced DNA single-strand breaks in mouse leukemia (L1210) cells. *Cancer Res* 1983;43(12 Pt 1):5718–5724.
- Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. *Biochemistry* 1984;23(6):1183–1188.
- Ban Y, Ho CW, Lin RK, et al. Activation of a novel ubiquitin-independent proteasome pathway when RNA polymerase II encounters a protein roadblock. *Mol Cell Biol* 2013;33(20):4008–4016.
- Long BH, Musial ST, Brattain MG. Single- and double-strand DNA breakage and repair in human lung adenocarcinoma cells exposed to etoposide and teniposide. *Cancer Res* 1985;45(7):3106–3112.
- Pommier Y. Drugging topoisomerases: lessons and challenges. *ACS Chem Biol* 2013;8(1):82–95.
- Zwelling LA, Michaels S, Erickson LC, et al. Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4-(9-acridinylamino) methanesulfon-m-anisidide and adriamycin. *Biochemistry* 1981;20(23):6553–6563.
- Wall ME, Wani MC. Camptothecin and taxol: discovery to clinic—thirteenth Bruce F. Cain Memorial Award Lecture. *Cancer Res* 1995;55:753–760.
- Pommier Y. Topoisomerase I inhibitors: camptothecins and beyond. *Nat Rev Cancer* 2006;6(10):789–802.
- Teicher BA. Next generation topoisomerase I inhibitors: rationale and biomarker strategies. *Biochem Pharmacol* 2008;75(6):1262–1271.
- Pommier Y, Cushman M. The indenisoquinoline noncamptothecin topoisomerase I inhibitors: update and perspectives. *Mol Cancer Ther* 2009;8(5):1008–1014.
- Douillard JY, Cunningham D, Roth AD, et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. *Lancet* 2000;355:1041–1047.
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. *N Engl J Med* 2000;343:905–914.
- Conroy T, Desseigne F, Tchou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. *N Engl J Med* 2011;364:1817–1825.
- Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. *J Clin Oncol* 2006;24:2038–2043.
- Schmittl A, Fischer von Weikersthal L, Sebastian M, et al. A randomized phase II trial of irinotecan plus carboplatin versus carboplatin treatment in patients with extended disease small-cell lung cancer. *Ann Oncol* 2006;17:663–667.
- Iyer L, King CD, Whittington PF, et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform IA1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. *J Clin Invest* 1998;101:847–854.
- Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP-glucuronosyltransferase IA1 gene predict the risk of severe neutropenia of irinotecan. *J Clin Oncol* 2004;22:1382–1388.
- Schaaf LJ, Hammond LA, Tipping SJ, et al. Phase I and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction. *Clin Cancer Res* 2006;12:3782–3791.
- ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. *J Clin Oncol* 1997;15:2183–2193.
- Ardizzoni A, Hansen H, Dombrowsky P, et al. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. *J Clin Oncol* 1997;15:2090–2096.
- Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. *J Clin Oncol* 2005;23:4626–4633.
- Baker SD, Heideman RL, Crom WR, et al. Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors. *Cancer Chemother Pharmacol* 1996;37:195–202.
- Schlupf T, Cheng J, Khin KT, et al. Pharmacokinetics and biodistribution of the camptothecin-polymer conjugate IT-101 in rats and tumor-bearing mice. *Cancer Chemother Pharmacol* 2006;57:654–662.
- Young C, Schlupf T, Hwang J, et al. CRLX101 (formerly IT-101)-A novel nanopharmaceutical of camptothecin in clinical development. *Curr Bioact Compd* 2011;7:8–14.
- Weiss GJ, Chao J, Neidhart JD, et al. First-in-human phase I/2a trial of CRLX101, a cyclodextrin-containing polymer-camptothecin nanopharmaceutical in patients with advanced solid tumor malignancies. *Invest New Drugs* 2013;31:986–1000.
- University of Chicago. A randomized phase II study of IV Topotecan versus CRLX101 in the second line treatment of recurrent small cell lung cancer. ClinicalTrials.gov Identifier: NCT01803269.
- Cerulean Pharma Inc. A randomized, phase 2, study to assess the safety and activity of CRLX101, a nanoparticle formulation of camptothecin, in patients with advanced non-small cell lung cancer who have failed one or two previous regimens of chemotherapy. ClinicalTrials Identifier: NCT01380769.
- Massachusetts General Hospital. A Phase II, 2-stage Trial of CRLX101-202 in recurrent ovarian, tubal and peritoneal cancer. ClinicalTrials.gov Identifier: NCT01652079.
- Vergote IB, Garcia A, Michá J et al. Randomized multicentre phase II trial comparing two schedules of irinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer. *J Clin Oncol* 2013;31(32):4060–4066.

56. Awada A, Garcia AA, Chan S et al. Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: a randomized phase 2 study. *Lancet Oncol* 2013;14(12):1216–1225.
57. Roswell Park Cancer Institute. A phase II study of single agent topoisomerase-I inhibitor polymer conjugate, Etirinotecan Pegol (NKTR-102), in patients with relapsed small cell lung cancer. ClinicalTrials Identifier: NCT01876446.
58. Abramson Cancer Center of the University of Pennsylvania. Phase 2 study of Etirinotecan Pegol (NKTR-102) in the treatment of patients with metastatic and recurrent non-small cell lung cancer (NSCLC) after failure of 2nd line treatment. ClinicalTrials Identifier: NCT01773109.
59. Nektar Therapeutics. A multicentre, open-label, randomized, phase 2 study to evaluate the efficacy and safety of NKTR-102 versus irinotecan in patients with second-line, irinotecan-naive, KRAS-mutant, metastatic colorectal cancer (mCRC). ClinicalTrials Identifier: NCT00856375.
60. Lawrence Recht. A phase II, single arm, open label study of NKTR-102 in bevacizumab-resistant high-grade glioma. ClinicalTrials Identifier: NCT01663012.
61. Nektar Therapeutics. The BEACON study (breast cancer outcomes with NKTR-102): a phase 3 open-label, randomized, multicenter study of NKTR-102 versus treatment of physician's choice (TPC) in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane and capecitabine. ClinicalTrials Identifier: NCT01492101.
62. Basili S, Moro S. Novel camptothecin derivatives as topoisomerase I inhibitors. *Expert Opin Ther Pat* 2009;19:555–574.
63. Choi CH, Lee YY, Song TJ, et al. Phase II study of belotecan, a camptothecin analogue, in combination with carboplatin for the treatment of recurrent ovarian cancer. *Cancer* 2011;117:2104–2111.
64. Rhee CK, Lee SH, Kim JS, et al. A multicentre phase II study of belotecan, a new camptothecin analogue, as a second-line therapy in patients with small cell lung cancer. *Lung Cancer* 2011;72(1):64–67.
65. Hwang JH, Lim MC, Seo SS, et al. Phase II study of belotecan (CKD 602) as a single agent in patients with recurrent or progressive carcinoma of the uterine cervix. *Jpn J Clin Oncol* 2011;41:624–629.
66. Frapolli R, Zucchetti M, Sessa C, et al. Clinical pharmacokinetics of the new oral camptothecin gimatecan: the inter-patient variability is related to alpha-1-acid glycoprotein plasma levels. *Eur J Cancer* 2010;46:505–516.
67. Pecorelli S, Ray-Coquard I, Tredan O, et al. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. *Ann Oncol* 2010;21:759–765.
68. Graham JS, Falk S, Samuel LM et al. A multi-centre dose escalation and pharmacokinetic study of diflomotecan in patients with advanced malignancy. *Cancer Chemother Pharmacol* 2009;63:945–952.
69. Trocóniz IF, Cendrós JM, Soto E, et al. Population pharmacokinetic/pharmacodynamics modeling of drug-induced adverse effects of a novel homocamptothecin analog, elomotecan (BN80927), in a Phase I dose finding study in patients with advanced solid tumors. *Cancer Chemother Pharmacol* 2012;70:239–250.
70. Takagi K, Dexheimer TS, Redon C, et al. Novel E-ring camptothecin keto analogues (S38809 and S39625) are stable, potent, and selective topoisomerase I inhibitors without being substrates of drug efflux transporters. *Mol Cancer Ther* 2007;6(12 Pt 1):3229–3238.
71. Lansiaux A, Léonce S, Kraus-Berthier L, et al. Novel stable camptothecin derivatives replacing the E-ring lactone by a ketone function are potent inhibitors of topoisomerase I and promising antitumor drugs. *Mol Pharmacol* 2007;72(2):311–319.
72. National Cancer Institute. A Phase I Study of Indenoisoquinolines LMP400 and LMP776 in Adults With Relapsed Solid Tumors and Lymphomas. ClinicalTrials Identifier: NCT01051635.
73. National Cancer Institute. A phase I trial of weekly Indenoisoquinolines LMP400 in adults with relapsed solid tumors and lymphomas. ClinicalTrials Identifier: NCT01794104.
74. Antony S, Agama KK, Miao ZH, et al. Novel indenoisoquinolines NSC 725776 and NSC 724998 produce persistent topoisomerase I cleavage complexes and overcome multidrug resistance. *Cancer Res* 2007;67:10397–10405.
75. Kurtzberg LS, Roth S, Krumbholz R, et al. Genz-644282, a novel non-camptothecin topoisomerase I inhibitor for cancer treatment. *Clin Cancer Res* 2011;17:2777–2787.
76. Genzyme, a Sanofi Company. Dose Escalation Study to Assess the Safety and Tolerability of Genz-644282 in Patients With Solid Tumors. ClinicalTrials Identifier: NCT00942799.
77. Capranico G, Zunino F, Kohn KW, et al. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. *Biochemistry* 1990;29(2):562–569.
78. Davies KJ, Doroshow JH. Redox cycling of anthracyclines by cardiac mitochondria. I. Anthracycline radical formation by NADH dehydrogenase. *J Biol Chem* 1986;261(7):3060–3067.
79. Doroshow JH, Davies KJ. Redox cycling of anthracyclines by cardiac mitochondria. II. Formation of superoxide anion, hydrogen peroxide, and hydroxyl radical. *J Biol Chem* 1986;261:3068–3074.
80. Schneider E, Cowan KH. Multiple drug resistance in cancer therapy. *Med J Aust* 1994;160(6):371–373.
81. Alvarez M, Paull K, Monks A, et al. Generation of a drug resistance profile by quantitation of mdr-1/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. *J Clin Invest* 1995;95(5):2205–2214.
82. Felix CA, Kolaris CP, Osheroff N. Topoisomerase II and the etiology of chromosomal translocations. *DNA Repair* 2006;5:1093–1108.
83. O'Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELXX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. *Ann Oncol* 2004;15(3):440–449.
84. Doroshow JH. Effect of anthracycline antibiotics on oxygen radical formation in rat heart. *Cancer Res* 1983;43(2):460–472.
85. Zhang S, Liu X, Bawa-Khalife T, et al. Identification of the molecular basis of doxorubicin-induced cardiotoxicity. *Nat Med* 2012;18:1639–1642.
86. Speyer J, Wasserheit C. Strategies for reduction of anthracycline cardiac toxicity. *Semin Oncol* 1998;25:525–537.
87. Chanan-Khan A, Srinivasan S, Czuczman MS. Prevention and management of cardiotoxicity from antineoplastic therapy. *J Support Oncol* 2004;2:251–256.
88. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. *Ann Intern Med* 1979;91:710–717.
89. Shan K, Lincoff AM, Young JB. Anthracycline-induced cardiotoxicity. *Ann Intern Med* 1996;125:47–58.
90. Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. *J Clin Oncol* 15(4):1318–1332.
91. Andoh T, Ishida R. Catalytic inhibitors of DNA topoisomerase II. *Biochim Biophys Acta* 1998;1400(1–3):155–171.
92. Kalam K, Marwick TH. Role of cardioprotective therapy for prevention of cardiotoxicity with chemotherapy: a systematic review and meta-analysis. *Eur J Clin Oncol* 2013;49:2900–2909.
93. Tannock IF, Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. *J Clin Oncol* 1996;14:1756–1764.
94. Reece DE, Elmongy MB, Barnett MJ, et al. Chemotherapy with high-dose cytosine arabinoside and mitoxantrone for poor-prognosis myeloid leukemias. *Cancer Invest* 1993;11:509–516.
95. Shenkenberg TD, Von Hoff DD. Mitoxantrone: a new anticancer drug with significant clinical activity. *Ann Intern Med* 1986;105:67–81.
96. Hollstein U. Actinomycin. Chemistry and mechanism of action. *Chem Rev* 1974;74(6):625–652.
97. Wassermann K, Markovits J, Jaxel C, et al. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. *Mol Pharmacol* 1990;38(1):38–45.
98. Biedler JL, Riehm H. Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. *Cancer Res* 1970;30:1174–1184.
99. Jaffe N, Paed D, Traggis D, et al. Improved outlook for Ewing's sarcoma with combination chemotherapy (vincristine, actinomycin D and cyclophosphamide) and radiation therapy. *Cancer* 1976;38(5):1925–1930.
100. Turan T, Karacay O, Tulunay G, et al. Results of EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) chemotherapy in gestational trophoblastic neoplasia. *Int J Gynecol Cancer* 2006;16(3):1432–1438.
101. Early KS, Albert DJ. Single agent chemotherapy (actinomycin D) in the treatment of metastatic testicular carcinoma. *South Med J* 1976;69(8):1017–1021.
102. Fernbach DJ, Martyn DT. Role of dactinomycin in the improved survival of children with Wilm's tumor. *JAMA* 1966;195(1222):1005–1009.
103. Maurer HM, Moon T, Donaldson M, et al. The intergroup rhabdomyosarcoma study: a preliminary report. *Cancer* 1977;40(5):2015–2026.
104. Chen GL, Yang L, Rowe TC, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase. *J Biol Chem* 1984;259(21):13560–13566.
105. Long BH, Musial ST, Brattain MG. Comparison of cytotoxicity and DNA breakage activity of cogeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship. *Biochemistry* 1984;23(6):1183–1188.
106. Ross W, Rowe T, Glisson B, et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. *Cancer Res* 1984;44:5857–5860.
107. Meresse P, Dechaux E, Monneret C, et al. Etoposide: discovery and medicinal chemistry. *Curr Med Chem* 2004;11:2443–2466.
108. Valkov NI, Gump JL, Engel R, et al. Cell density-dependent VP-16 sensitivity of leukaemic cells is accompanied by the translocation of topoisomerase IIalpha from the nucleus to the cytoplasm. *Br J Haematol* 2000;108:331–345.
109. Takano H, Kohno K, Ono M, et al. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. *Cancer Res* 1991;51:3951–3957.
110. Sundström S, Bremnes RM, Kaasa S, et al. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. *J Clin Oncol* 2002;20:4665–4672.
111. Nichols CR, Catalano PJ, Crawford ED, et al. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: an Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. *J Clin Oncol* 1998;16:1287–1293.

112. Leu BL, Huang JD. Inhibition of intestinal P-glycoprotein and effects on etoposide absorption. *Cancer Chemother Pharmacol* 1995;35:432–436.
113. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. *J Clin Oncol* 1999;17:569–577.
114. Maluf PT, Odone Filho V, Cristofani LM, et al. Teniposide plus cytarabine as intensification therapy and in continuation therapy for advanced nonlymphoblastic lymphomas of childhood. *J Clin Oncol* 1994;12:1963–1968.
115. Rivera C, Bowman WP, Murphy SB, et al. VM-26 with prednisone and vincristine for treatment of refractory acute lymphocytic leukemia. *Med Pediatr Oncol* 1982;10:439–446.
116. Lovett BD, Lo Nigro L, Rappaport EF, et al. Near-precise interchromosomal recombination and functional DNA topoisomerase II cleavage sites at MLL and AF-4 genomic breakpoints in treatment-related acute lymphoblastic leukemia with t(4;11) translocation. *Proc Natl Acad Sci U S A* 2001;98(17):9802–9807.
117. Cowell IG, Sondka Z, Smith K, et al. Model for MLL translocations in therapy-related leukemia involving topoisomerase IIb-mediated DNA strand breaks and gene proximity. *Proc Natl Acad Sci U S A* 2012;109(23):8989–8994.
118. Azarova AM, Lyu YL, Lin CP, et al. Roles of DNA topoisomerases II isozymes in chemotherapy and secondary malignancies. *Proc Natl Acad Sci U S A* 2007;104:11014–11019.
119. Changela A, DiGate RJ, Mondragón A. Structural studies of E. Coli topoisomerase III-DNA complexes reveal a novel type IA topoisomerase-DNA conformational intermediate. *J Mol Biol* 2007;368:105–118.
120. Bertrand R, O'Connor PM, Kerrigan D, et al. Sequential administration of camptothecin and etoposide circumvents the antagonistic cytotoxicity of simultaneous drug administration in slowly growing human colon carcinoma HT-29 cells. *Eur J Cancer* 1992;28A(4–5):743–748.
121. Miller AA, Al Omari A, Murry DJ, et al. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer. *Lung Cancer* 2006;54:379–385.
122. Rose PG, Markham M, Bell JG, et al. Sequential prolonged oral topotecan and prolonged oral etoposide as second-line therapy in ovarian or peritoneal carcinoma: a phase I Gynecologic Oncology Study Group study. *Gynecol Oncol* 2006;102:236–239.
123. Kummar S, Chen A, Ji J, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. *Cancer Res* 2011;71(17):5626–5634.
124. Pfister TD, Hollingshead M, Kinders RJ, et al. Development and validation of an immunoassay for quantification of topoisomerase I in solid tumor tissues. *PLoS One* 2012;7:e50494.
125. Kinders RJ, Hollingshead M, Lawrence S, et al. Development of a validated immunofluorescence assay for gHZAX as a pharmacodynamics marker of topoisomerase I inhibitor activity. *Clin Cancer Res* 2010;16:5447–5457.